GNAI2

G protein subunit alpha i2

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
GNAI2 mutation2
(oncogenic)	EZB Diffuse Large B-Cell Lymphoma	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11943 The study identified recurrently mutated genes in DLBCL using whole genome sequencing. PMID 23699601 · Morin et al., 2013 · Open in CIViC	civic
〃	Burkitt Lymphoma	Oncogenic	E	Supports Oncogenicity	3	submitted	EID11839 Mutated at high frequency in both DLBCL and BL PMID 30617194 · Grande et al., 2019 · Open in CIViC	civic

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved4 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Kidney Renal Clear Cell Carcinoma TCGA-KIRC	Clear Cell Renal Cell Carcinoma	Ssm

Literature

Data not yet available

No publication linked to this gene yet.